Article précédent

Pay for delay agreements: An overview of EU and US Case Law

Are pay-for-delay agreements still a hot topic for competition authorities and courts? The answer, albeit reckless, is definitely “yes”. As the years go by, competition authorities still seem determined to fight these agreements, which are sometimes referred to as “patent settlements” or “reverse payment settlements”. Fundamentally, there are several reasons why competition authorities on both sides of the Atlantic remain vigilant. In the United States, the Actavis decision of the Supreme Court [1], handed down in 2013, did not finally prohibit pharmaceutical companies from concluding pay-for-delay agreements. Strictly speaking, the decision only established that such deals may have anticompetitive effects. By rejecting the per se rule and by adopting the rule of reason, the Supreme Court

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • University of Grenoble Alpes

Citation

Walid Chaiehloudj, Pay for delay agreements : An overview of EU and US Case Law, 5 mai 2021, e-Competitions Pay-for-delay agreements, Art. N° 99337

Visites 1014

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues